Affinity Asset Advisors »

Enliven Therapeutics shares owned by Affinity Asset Advisors

Quarter-by-quarter ownership of Enliven Therapeutics (ELVN) shares owned by Affinity Asset Advisors from 13F filings

Historical chart of Affinity Asset Advisors investment in Enliven Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Enliven Therapeutics held by Affinity Asset Advisors consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Enliven Therapeutics by Affinity Asset Advisors

Quarter filed Position value Share count Share price at filing
2025-09-30 $8.2M 400k 20.47
2025-06-30 $8.0M 400k 20.06

More positions owned by Affinity Asset Advisors

Insmed Com Par $.01 (INSM)
Verona Pharma Sponsored Ads (VRNA)
Spdr S&p 500 Etf Tr Tr Unit (SPY)
Xenon Pharmaceuticals (XENE)
Madrigal Pharmaceuticals (MDGL)
Apogee Therapeutics (APGE)
Arcellx Common Stock (ACLX)
Alkermes SHS (ALKS)
Nuvalent Inc-a (NUVL)
Abivax Sa Sponsored Ads (ABVX)
Mineralys Therapeutics (MLYS)
Teva Pharmaceutical Inds Sponsored Ads (TEVA)
Merus N V (MRUS)
Centessa Pharmaceuticals Sponsored Ads (CNTA)
Lexeo Therapeutics (LXEO)

View all positions for Affinity Asset Advisors

Top funds holding Enliven Therapeutics

OrbiMed Advisors
FMR
Commodore Capital
Fairmount Funds Management
BlackRock
VR Adviser
Polar Capital Holdings
Vanguard Group
Henderson Group
Novo A/S
Pictet Asset Management Holding SA
Blackstone Group
Capital Research Global Investors
Citadel Advisors
Vestal Point Capital

View all funds holding Enliven Therapeutics